UPDATED: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday. Merck KGaA confirmed the talks but said it's not certain a deal will come together.
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday. Merck KGaA confirmed the talks but said it's not certain a deal will come together.
